Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions

Peritoneal Dialysis International

Volumn 20, Issue 6, 2001, Pages 643-651

  Lee, J H ^a   Reddy, D K ^a   Saran, R ^a   Moore, H L ^a   Twardowski, Z J ^a   Nolph, K D ^a   Khanna, R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Advanced glycosylation end products; Dialysis solutions; Glycosylation; Icodextrin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; DIALYSIS FLUID; DIANEAL; EXTRANEAL; GENTAMICIN; GLUCOSE; ICODEXTRIN; METHOXYFLURANE; MONOCLONAL ANTIBODY; STREPTOZOCIN; UREA; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSATE; EQUILIBRIUM DIALYSIS; IMMUNOHISTOCHEMISTRY; IMPLANTATION; MALE; MEMBRANE TRANSPORT; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; RAT STRAIN; TISSUE SECTION; UREA BLOOD LEVEL;

EID: 0035110781     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002000611     Document Type: Article

References (36)

1. CAPD systems and solutions
2. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
3. Compatibility of peritoneal dialysis fluids containing alternative osmotic agents with cells present in the peritoneal cavity
4. Aspects of new solutions for peritoneal dialysis
5. Categorization of the ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients
6. Kinetics of icodextrin
7. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solution in CAPD
8. Improved ultrafiltration in CCPD patients using icodextrin (I) instead glucose (G) during the long daytime dwell (Abstract)
9. Icodextrin's effects on peritoneal transport
10. Glycation and advanced glycation end-product formation with icodextrin and dextrose
11. Advanced glycosylation end-products
12. Nonenzymatic glycosylation and glucose-dependent cross-linking protein
13. 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes
14. Increase in 3-deoxyglucosone levels in diabetic rat plasma
15. 2-microglobulin with advanced glycation end-products (Abstract)
16. Pathogenic effects of advanced glycosylation: Biochemical, biologic, clinical implications for diabetes and aging
17. Recent progress on the biologic and clinical significance of advanced glycosylation end-products
18. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
19. Serum advanced glycosylation end-products: A new class of uremic toxins?
20. Non-enzymatic glycosylation and the chronic complications of diabetes. An overview
21. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular diseases
22. Advanced glycosylation end products in peritoneal tissue with different solutions
23. A chronic catheter model for PD exchanges in the ambulatory rat (Abstract)
24. Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis
25. Advanced glycation end products in peritoneal dialysis
26. Glycation of albumin with icodextrin (Abstract)
27. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis
28. Microcirculation and diabetes
29. Pathophysiological description of the ultrastructural changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis
30. The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen
31. Laminin alterations after in vitro nonenzymatic glycosylation
32. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
33. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD
34. Biocompatibility of peritoneal dialysis fluids (Editorial)
35. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis
36. Abdominal wall thickness as a means of assessing peritoneal fibrosis in mice